AbbVie Inc (ABBV)vsQuidel Corporation (QDEL)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
QDEL
Quidel Corporation
$10.70
-16.67%
HEALTHCARE · Cap: $943.60M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2369% more annual revenue ($66.01B vs $2.67B). ABBV leads profitability with a 15.7% profit margin vs -39.2%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
QDEL
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Margin of Safety
+87.7%
Fair Value
$235.00
Current Price
$10.70
$224.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
2.8% revenue growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : QDEL
The strongest argument for QDEL centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : QDEL
The primary concerns for QDEL are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 1.73 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a mature stock while QDEL is a turnaround play — different risk/reward profiles.
QDEL carries more volatility with a beta of 0.78 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 42/100), backed by strong 15.7% margins and 10.3% revenue growth. QDEL offers better value entry with a 87.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Quidel Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health, gastrointestinal disease, and toxicology applications globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?